Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress

1 May 2020

Abstract excerpt

Prostate cancers (PCs) with loss of the potent tumor suppressors TP53 and RB1 exhibit poor outcomes. TP53 and RB1 also influence cell plasticity and are frequently lost in PCs with neuroendocrine (NE) differentiation. Therapeutic strategies that address these aggressive variant PCs are urgently needed. Using deep genomic profiling of 410 metastatic biopsies, we determine the relationships between combined TP53...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32460015
DOI: 10.1016/j.celrep.2020.107669

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication StressPMID 32460015Read ↗

Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate CancerSemantic proximity Read ↗

TP53 Deficiency in the Natural History of Prostate CancerSemantic proximity Read ↗

Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor SignalingSemantic proximity Read ↗

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Semantic proximity Read ↗

Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolutionSemantic proximity Read ↗

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical OutcomesSemantic proximity Read ↗

Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53.Semantic proximity Read ↗

Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma.Semantic proximity Read ↗

Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.Semantic proximity Read ↗

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancerSemantic proximity Read ↗

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancerSemantic proximity Read ↗

Novel insights in cell cycle dysregulation during prostate cancer progressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.